These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32279215)

  • 21. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.
    Wood RC; Stewart DW; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B
    Pharmacotherapy; 2015 Jul; 35(7):663-9. PubMed ID: 26095331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience.
    Akhtar T; Fratti JDC; Mattumpuram J; Fugar S; Uprety A; Nwaichi C; Torres A; Mann H; Golzar Y
    Int J Cardiol; 2020 Dec; 320():78-82. PubMed ID: 32598991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
    Tellor KB; Patel S; Armbruster AL; Daly MW
    J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study.
    Tsu LV; Berry A; Wald E; Ehrlich C
    Consult Pharm; 2015 Jul; 30(7):395-402. PubMed ID: 26173191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
    Vimalesvaran K; Dockrill SJ; Gorog DA
    Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
    Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
    Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for ecchymosis in patients receiving rivaroxaban for thromboprophylaxis after total knee arthroplasty: a retrospective cohort study.
    Xiao L; Zheng X; Jiang H; Huang W; Qiu F; Li X
    J Clin Pharm Ther; 2021 Oct; 46(5):1281-1287. PubMed ID: 33768580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.